SCHEMBL10690765

SCHEMBL10690765

COc1ccc(-c2cc(=O)n3ccccc3n2)cc1OC

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 7/20 0.61
ALDH1A1 P00352 7/20 0.61
HSD17B10 Q99714 5/20 0.61
HPGD P15428 5/20 0.61
RAB9A P51151 5/20 0.61
SMN1; SMN2 Q16637 5/20 0.61
MAPK1 P28482 4/20 0.61
NPC1 O15118 4/20 0.61
TSHR P16473 3/20 0.61
TP53 P04637 3/20 0.61
PKM P14618 2/20 0.61
MAPT P10636 4/20 0.50
MEN1 O00255 3/20 0.50
KMT2A Q03164 3/20 0.50
HTT P42858 3/20 0.50
TDP1 Q9NUW8 1/20 0.50
USP2 O75604 1/20 0.50
ATM Q13315 1/20 0.50
KLK7 P49862 1/20 0.49
L3MBTL1 Q9Y468 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8108255 0.84 KDM4E (0.65) KDM4EALDH1A1HSD17B10RAB9ASMN1; SMN2
SCHEMBL21902786 0.83 TP53 (0.47) KDM4EALDH1A1HSD17B10HPGDRAB9A
SCHEMBL7925220 0.82 MEN1 (0.57) KDM4EALDH1A1HSD17B10HPGDRAB9A
SCHEMBL7920089 0.81 HSP90AA1 (0.49) KDM4EALDH1A1HSD17B10HPGDSMN1; SMN2
SCHEMBL15176054 0.80 SMN1; SMN2 (0.54) KDM4EALDH1A1HSD17B10HPGDRAB9A
SCHEMBL30602254 0.80 SMN1; SMN2 (0.54) KDM4EALDH1A1HSD17B10HPGDRAB9A
SCHEMBL15176064 0.80 MAPT (0.50) KDM4EALDH1A1HSD17B10HPGDRAB9A
SCHEMBL15174164 0.80 ALDH1A1 (0.51) KDM4EALDH1A1HSD17B10HPGDRAB9A
SCHEMBL8099804 0.79 RAB9A (0.49) KDM4EALDH1A1HSD17B10HPGDRAB9A
SCHEMBL1659994 0.78 KDM4E (0.52) KDM4EALDH1A1HSD17B10HPGDRAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240067646-A1 COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY HOFFMANN-LA ROCHE INC. 2024-02-29 US disclosed
US-11753407-B2 Compounds for treating spinal muscular atrophy PTC THERAPEUTICS, INC. (US) 2023-09-12 US disclosed
US-20210276999-A1 COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY HOFFMANN-LA ROCHE INC. 2021-09-09 US disclosed
US-10851101-B2 Compounds for treating spinal muscular atrophy PTC THERAPEUTICS, INC. (US) 2020-12-01 US disclosed
US-20180105526-A1 COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY PTC THERAPEUTICS INC (US) 2018-04-19 US disclosed
US-9879007-B2 Compounds for treating spinal muscular atrophy PTC THERAPEUTICS, INC. (US) 2018-01-30 US disclosed
US-20170129885-A1 COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY HOFFMANN-LA ROCHE INC. 2017-05-11 US disclosed
US-9586955-B2 Compounds for treating spinal muscular atrophy PTC THERAPEUTICS, INC. (US) 2017-03-07 US disclosed
US-20150005289-A1 COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY HOFFMANN-LA ROCHE INC. 2015-01-01 US disclosed
EP-2812004-A2 COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY PTC Therapeutics, Inc. (US) 2014-12-17 EP disclosed
WO-2013119916-A2 COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY PTC THERAPEUTICS, INC. (US) 2013-08-15 WO disclosed
US-4725600-A Pyrimidine compounds having activity as a cardiotonic anti-hypertensive cerebrovascular vasodilator and anti-platelet aggregation agent FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1988-02-16 US disclosed
EP-0168262-A2 Pyrimidine derivatives, processes for preparation thereof and use thereof FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1986-01-15 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240067646-A1 COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY SMN1; SMN2, CPT1B, GYS1 KDM4E 2384/4885ALDH1A1 1088/4885HSD17B10 863/4885
US-20150005289-A1 COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY SMN1; SMN2, CPT1B, GYS1 KDM4E 1926/4885ALDH1A1 1461/4885HSD17B10 952/4885
US-20180105526-A1 COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY SMN1; SMN2, CPT1B, GYS1 KDM4E 1926/4885ALDH1A1 1461/4885HSD17B10 952/4885
US-20210276999-A1 COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY SMN1; SMN2, CPT1B, GYS1 KDM4E 2384/4885ALDH1A1 1088/4885HSD17B10 863/4885
US-20170129885-A1 COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY SMN1; SMN2, CPT1B, GYS1 KDM4E 1926/4885ALDH1A1 1461/4885HSD17B10 952/4885
US-10851101-B2 Compounds for treating spinal muscular atrophy SMN1; SMN2, CPT1B, GYS1 KDM4E 2384/4885ALDH1A1 1088/4885HSD17B10 863/4885
US-11753407-B2 Compounds for treating spinal muscular atrophy SMN1; SMN2, CPT1B, GYS1 KDM4E 1370/4885ALDH1A1 1651/4885HSD17B10 1533/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.